Overview

A Study of Efinopegdutide in Healthy Obese Participants (MK-6024-015)

Status:
COMPLETED
Trial end date:
2025-02-18
Target enrollment:
Participant gender:
Summary
The goal of this study is to learn about the safety of efinopegdutide (MK-6024) and how well overweight healthy people tolerate it. Researchers also want to know what happens to efinopegdutide in a person's body over time when taken as a single dose (Part 1) or as multiple doses (Part 2). In addition, the study will assess the amount of acetaminophen in the blood after receiving different strength doses of efinopegdutide (Part 2 only).
Phase:
PHASE1
Details
Lead Sponsor:
Merck Sharp & Dohme LLC
Treatments:
Acetaminophen